Last 913.60 INR
Change Today -27.05 / -2.88%
Volume 2.4M
WPL On Other Exchanges
Symbol
Exchange
Natl India
As of 6:06 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

wockhardt ltd (WPL) Snapshot

Open
949.80
Previous Close
940.65
Day High
964.95
Day Low
902.20
52 Week High
12/12/14 - 1,087
52 Week Low
01/27/14 - 385.20
Market Cap
100.5B
Average Volume 10 Days
2.2M
EPS TTM
76.64
Shares Outstanding
110.0M
EX-Date
11/13/14
P/E TM
11.9x
Dividend
20.00
Dividend Yield
2.74%
Current Stock Chart for WOCKHARDT LTD (WPL)

Related News

No related news articles were found.

wockhardt ltd (WPL) Related Businessweek News

No Related Businessweek News Found

wockhardt ltd (WPL) Details

Wockhardt Limited, a pharmaceutical and biotechnology company, together with its subsidiaries, manufactures and markets pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It provides pharmaceutical products in various dosage forms, such as sterile injectables and lyophilised products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; and value-added generics. Its biopharmaceutical products include Glargine that is recombinant long-acting insulin; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing and packaging services for sterile injectables, lyophilisation, solid dose, liquids/ointments/creams, sachets and powders, and specialized products; API manufacturing services; and contract research services. Its research activities comprise pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery systems, new drug discovery programs, and process engineering for APIs. The company develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. Wockhardt Limited offers its products in India, the United States, Europe, and other countries. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Khorakiwala Holdings and Investments Private Limited.

8,600 Employees
Last Reported Date: 08/19/14
Founded in 1999

wockhardt ltd (WPL) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 13.3M
Founder, Executive Chairman, Group Chief Exec...
Total Annual Compensation: 4.8M
Executive Director, Member of Share Allotment...
Total Annual Compensation: 13.3M
Compensation as of Fiscal Year 2014.

wockhardt ltd (WPL) Key Developments

Wockhardt Launches Hospital in Mumbai

Wockhardt opened a 350-bed hospital in South Mumbai. Set up at an estimated INR 3,000 million, the tertiary care hospital bundles together major specialities, including cardiac and critical care services. Two more hospitals are on Wockhardt's radar in Delhi and another in suburban Mumbai.

Wockhardt Limited Declares an Interim Dividend for the Financial Year 2014-15, Payable on or Before December 2, 2014

Wockhardt Limited announced that Board of Directors of the company at their meeting held on November 3, 2014 have declared an interim dividend of INR 20 per equity share of face value of INR 5 each that is at the rate 400 % for the financial year 2014-15 on 110,040,403 equity shares of the company. The Board has fixed record date for the purpose of payment of interim dividend as November 14, 2014. The interim dividend will be paid to the shareholders of the company on or before December 2, 2014.

Wockhardt Ltd. Announces Unaudited Consolidated and Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Wockhardt Ltd. announced unaudited consolidated and standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, on consolidated basis, the company reported net sales /income from operations was INR 9,478.6 million compared to INR 11,969.7 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 1,280.5 million compared to INR 1,568.4 million a year ago. Profit from ordinary activities before tax was INR 820.4 million against INR 1,297.2 million a year ago. Net profit after taxes, minority interest & share of profit of associates was INR 36.3 million or INR 0.33 per basic and diluted share before and after extraordinary items compared to net profit after taxes, minority interest & share of profit of associates of INR 1,385.0 million or INR 12.46 per diluted share before and after extraordinary items a year ago. For the six months, on consolidated basis, the company reported net sales /income from operations was INR 19,390.5 million compared to INR 25,553.4 million a year ago. Profit from operations before other income, finance cost and exceptional items was INR 1,523.9 million compared to INR 5,456.3 million a year ago. Profit from ordinary activities before tax was INR 1,071.8 million against INR 4,909.4 million a year ago. Net profit after taxes, minority interest & share of profit of associates was INR 235.8 million or INR 2.12 per diluted share before and after extraordinary items compared to net profit after taxes, minority interest & share of profit of associates of INR 4,618.1 million or INR 41.55 per diluted share before and after extraordinary items a year ago. For the quarter, on standalone basis, the company reported net sales /income from operations was INR 4,670.5 million compared to INR 4,601.5 million a year ago. Loss from operations before other income, finance cost and exceptional items was INR 81.5 million compared to INR 121.0 million a year ago. Profit from ordinary activities before tax was INR 4,184.3 million against INR 1,464.1 million a year ago. Net profit was INR 3,659.4 million or INR 32.89 per diluted share before and after extraordinary items compared to net profit of INR 1,345.7 million or INR 12.11 per diluted share before and after extraordinary items a year ago. For the six months, on standalone basis, the company reported net sales /income from operations was INR 9,524.9 million compared to INR 9,614.7 million a year ago. Loss from operations before other income, finance cost and exceptional items was INR 14.2 million compared to profit from operations before other income, finance cost and exceptional items of INR 290.6 million a year ago. Profit from ordinary activities before tax was INR 4,220.2 million against INR 1,632.4 million a year ago. Net profit was INR 3,712.9 million or INR 33.39 per diluted share before and after extraordinary items compared to net profit of INR 1,504.6 million or INR 13.54 per diluted share before and after extraordinary items a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WPL:IN 913.60 INR 0.00

WPL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,514 INR 0.00
Cipla Ltd/India 618.95 INR 0.00
Endo International PLC $73.00 USD +1.69
Ipca Laboratories Ltd 709.90 INR 0.00
Torrent Pharmaceuticals Ltd 1,045 INR 0.00
View Industry Companies
 

Industry Analysis

WPL

Industry Average

Valuation WPL Industry Range
Price/Earnings 24.7x
Price/Sales 2.3x
Price/Book 2.9x
Price/Cash Flow 18.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WOCKHARDT LTD, please visit www.wockhardt.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.